Hansa Biopharma, (Nasdaq Stockholm: HNSA), a Sweden-based company involved in enzyme technology for rare immunological conditions, announced on Friday that it has named Dr Hitto Kaufmann as its new chief scientific officer (CSO) effective 1 December 2023.

In the new role, Dr Kaufmann will be responsible for all research, early development, translational and manufacturing activities and will report to president and chief executive officer Soren Tulstrup, and serves as a member of Hansa's executive committee.

Dr Kaufmann has 20 years of experience in research, development, and manufacturing. He has served as chief scientific officer at Pieris Pharmaceuticals. Presently, he is the member of the Scientific Advisory Board of Instituto de Biologia Experimental e Tecnologica (iBET). He has also served for five years at Sanofi, where he held several executive positions in Industrial Affairs and R&D. He has spent over a decade at Boehringer Ingelheim, and prior to his departure he was the vice president of Process Sciences in the Biopharmaceuticals division. He started his career as a research scientist at the Walter and Eliza Hall Institute in Melbourne.